# Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease

> **NCT07733349** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai UniXell Biotechnology Co., Ltd** · enrollment: 12 (estimated)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** UX-DA003

## Key facts

- **NCT ID:** NCT07733349
- **Lead sponsor:** Shanghai UniXell Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-03
- **Primary completion:** 2029-08-31
- **Final completion:** 2032-08-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07733349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07733349, "Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07733349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*